UB Paderborn / Katalog / Suche / in CDI

Sie befinden Sich nicht im Netzwerk der Universität Paderborn. Der Zugriff auf elektronische Ressourcen ist gegebenenfalls nur via VPN oder Shibboleth (DFN-AAI) möglich. mehr Informationen...

1 – 25 von 5.357

Sortiert nach

Trastuzumab Deruxtecan versus Trastuzumab Emtansine for Breast Cancer

The New England journal of medicine, 2022-03, Vol.386 (12), p.1143-1154

2022

Volltextzugriff (PDF)

Trastuzumab Deruxtecan in HER2-Positive Metastatic Breast Cancer Patients with Brain Metastases: A DESTINY-Breast01 Subgroup Analysis

Cancer discovery, 2022-12, Vol.12 (12), p.2754-2762

2022

Volltextzugriff (PDF)

Novel HER2-Targeting Antibody-Drug Conjugates of Trastuzumab Beyond T-DM1 in Breast Cancer: Trastuzumab Deruxtecan(DS-8201a) and (Vic-)Trastuzumab Duocarmazine (SYD985)

European journal of medicinal chemistry, 2019-12, Vol.183, p.111682, Article 111682

2019

Volltextzugriff (PDF)

The evolving therapeutic landscape of trastuzumab-drug conjugates: Future perspectives beyond HER2-positive breast cancer

Cancer treatment reviews, 2023-02, Vol.113, p.102500, Article 102500

2023

Volltextzugriff (PDF)

Transient Competitive Inhibition Bypasses the Binding Site Barrier to Improve Tumor Penetration of Trastuzumab and Enhance T-DM1 Efficacy

Cancer research (Chicago, Ill.), 2021-08, Vol.81 (15), p.4145-4154

2021

Volltextzugriff (PDF)

Trastuzumab Emtansine Plus Pertuzumab Versus Taxane Plus Trastuzumab Plus Pertuzumab After Anthracycline for High-Risk Human Epidermal Growth Factor Receptor 2-Positive Early Breast Cancer: The Phase III KAITLIN Study

Journal of clinical oncology, 2022-02, Vol.40 (5), p.438-448

2022

Volltextzugriff (PDF)

Clinical perspective: Antibody-drug conjugates for the treatment of HER2-positive breast cancer

Molecular therapy, 2023-07, Vol.31 (7), p.1874-1903

2023

Volltextzugriff (PDF)

Neoadjuvant T-DM1/pertuzumab and paclitaxel/trastuzumab/pertuzumab for HER2 + breast cancer in the adaptively randomized I-SPY2 trial

Nature communications, 2021-11, Vol.12 (1), p.6428-11, Article 6428

2021

Volltextzugriff (PDF)

Efficacy and safety of HER2 inhibitors in combination with or without pertuzumab for HER2-positive breast cancer: a systematic review and meta-analysis

BMC cancer, 2019-10, Vol.19 (1), p.973-15, Article 973

2019

Volltextzugriff (PDF)

Adjuvant Trastuzumab Emtansine Versus Paclitaxel and Trastuzumab in Stage I HER2-Positive Breast Cancer: The ATEMPT Trial

Annals of surgical oncology, 2024-03, Vol.31 (3), p.1423-1427

2024

Volltextzugriff (PDF)

HER2DX ERBB2 mRNA expression in advanced HER2-positive breast cancer treated with T-DM1

JNCI : Journal of the National Cancer Institute, 2023-03, Vol.115 (3), p.332-336

2023

Volltextzugriff (PDF)

Impact of Anti-HER2 Treatments Combined With Atezolizumab on the Tumor Immune Microenvironment in Early or Metastatic Breast Cancer: Results From a Phase Ib Study

Clinical breast cancer, 2021-12, Vol.21 (6), p.539-551

2021

Volltextzugriff (PDF)

Cost–utility analysis of trastuzumab deruxtecan versus trastuzumab emtansine in HER2-positive metastatic breast cancer in Chinese setting

Journal of cancer research and clinical oncology, 2023-12, Vol.149 (20), p.17933-17942

2023

Volltextzugriff (PDF)

An anti-EGFR antibody-drug conjugate overcomes resistance to HER2-targeted drugs

Cancer letters, 2023-02, Vol.554, p.216024-216024, Article 216024

2023

Volltextzugriff (PDF)

Targeting TACC3 Induces Immunogenic Cell Death and Enhances T-DM1 Response in HER2-Positive Breast Cancer

Cancer research (Chicago, Ill.), 2024-05, Vol.84 (9), p.1475

2024

Volltextzugriff (PDF)

Antibody drug conjugates targeting HER2: Clinical development in metastatic breast cancer

Breast (Edinburgh), 2022-12, Vol.66, p.217-226

2022

Volltextzugriff (PDF)

Tumor biomarkers and efficacy in patients treated with trastuzumab emtansine + pertuzumab versus standard of care in HER2-positive early breast cancer: an open-label, phase III study (KRISTINE)

Breast cancer research : BCR, 2023-01, Vol.25 (1), p.2-14, Article 2

2023

Volltextzugriff (PDF)

Biomarker Data from the Phase III KATHERINE Study of Adjuvant T-DM1 versus Trastuzumab for Residual Invasive Disease after Neoadjuvant Therapy for HER2-Positive Breast Cancer

Clinical cancer research, 2023-04, Vol.29 (8), p.1569-1581

2023

Volltextzugriff (PDF)

Trastuzumab deruxtecan versus trastuzumab emtansine for patients with human epidermal growth factor receptor 2-positive metastatic breast cancer: A cost-effectiveness analysis

Breast (Edinburgh), 2022-12, Vol.66, p.191-198

2022

Volltextzugriff (PDF)

Prevalence and Therapeutic Targeting of High-Level ERBB2 Amplification in NSCLC

Journal of thoracic oncology, 2024-05, Vol.19 (5), p.732-748

2024

Volltextzugriff (PDF)

HER2 Genetic Intratumor Heterogeneity Is Associated With Resistance to Trastuzumab and Trastuzumab Emtansine Therapy in Recurrent High-Grade Endometrial Cancer

Modern pathology, 2023-11, Vol.36 (11), p.100299-100299, Article 100299

2023

Volltextzugriff (PDF)

A second-generation antibody–drug conjugate to treat HER2-positive breast cancer

The Lancet (British edition), 2023-01, Vol.401 (10371), p.80-81

2023

Volltextzugriff (PDF)

T-DXd Keeps Shining in Breast Cancer

Cancer discovery, 2023-02, Vol.13 (2), p.254-254

2023

Volltextzugriff (PDF)

NSABP FB-10: a phase Ib/II trial evaluating ado-trastuzumab emtansine (T-DM1) with neratinib in women with metastatic HER2-positive breast cancer

Breast cancer research : BCR, 2024-04, Vol.26 (1), p.69-69, Article 69

2024

Volltextzugriff (PDF)

CyTOF analysis revealed platelet heterogeneity in breast cancer patients received T-DM1 treatment

Clinical immunology (Orlando, Fla.), 2024-06, Vol.263, p.110227-110227, Article 110227

2024

Volltextzugriff (PDF)

1 – 25 von 5.357

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(4.945)
Mit Volltextzugriff
(4.414)

Publikationsform

Sprache

15 weitere anzeigen...

Weniger anzeigen...

Erscheinungsjahr

n.n

n.n

Thema

Humans
(5.289)
Trastuzumab
(4.350)
Science & Technology
(4.296)
Female
(4.287)
Life Sciences & Biomedicine
(4.123)
Breast Neoplasms - Drug Therapy
(3.477)
Oncology
(2.951)
Antineoplastic Agents - Therapeutic Use
(2.176)
Antibodies, Monoclonal, Humanized
(2.091)
Breast Cancer
(2.081)
Antineoplastic Combined Chemotherapy Protocols - Therapeutic Use
(1.926)
Breast Neoplasms - Pathology
(1.875)
Middle Aged
(1.790)
Receptor, Erbb-2 - Metabolism
(1.697)
Antibodies, Monoclonal - Therapeutic Use
(1.691)
Adult
(1.396)
Aged
(1.373)
Trastuzumab - Therapeutic Use
(1.317)
Treatment Outcome
(1.115)
Tumors
(1.077)

15 weitere anzeigen...

Weniger anzeigen...

Kollektion

MEDLINE
(5.353)
EZB-FREE-00999 freely available EZB journals
(2.517)
Ingenta
(2.218)
Journals@Ovid Full Text
(2.201)
IngentaConnect Journals
(1.357)
Publisher website
(1.167)
Elsevier ScienceDirect Journals Complete
(967)
SpringerLink Journals - AutoHoldings
(886)
SpringerLINK Contemporary (Konsortium Baden-Württemberg)
(615)
Elsevier Journal Backfiles on ScienceDirect (DFG Nationallizenzen)
(544)
Wiley Journals
(413)
Taylor & Francis
(296)
Taylor & Francis Journals Auto-Holdings Collection
(295)
Nature International Weekly Journal of Science
(242)
Nexis Uni (LexisNexis)
(241)
Wiley Online Library
(217)
Taylor & Francis Online
(178)
Oxford Journals
(144)
Oxford Journals 2020 Medicine
(130)
SAGE Journals
(105)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

Journal Of Clinical Oncology
(202)
Breast Cancer Research And Treatment
(188)
Gan To Kagaku Ryoho
(183)
Annals Of Oncology
(163)
Clinical Breast Cancer
(139)
Clinical Cancer Research
(119)
Breast
(107)
The Oncologist
(88)
The oncologist
(82)
The Lancet Oncology
(77)

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(7)